文献速递前列腺癌

PROMIS试验中经直肠超声活检与经会阴模板定位穿刺活检按多参数磁共振成像评分分层的比较

Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
PubMed 文献 · J Urol · 2019-07-23

PROMIS研究纳入740例初次活检男性,其中576例完成多参数磁共振成像、经会阴模板定位穿刺和经直肠超声引导系统穿刺,活检均盲法进行。主要临床显著前列腺癌定义为Gleason 4+3或以上,或任何分级最大癌芯长度≥6 mm。结果显示经直肠超声引导系统穿刺敏感性低(35%–52%),多参数磁共振成像评分1–2分者中仅1/20发现Gleason 3+4疾病。

要点

  • 多参数磁共振成像评分1–2分的150例中,仅8例(5.1%)经直肠超声引导系统穿刺发现Gleason 3+4或以上疾病。
  • 经直肠超声引导系统穿刺对临床显著前列腺癌的敏感性在各多参数磁共振成像评分中稳定且低,为35%至52%。
  • 多参数磁共振成像评分3–5分且未行靶向穿刺而仅接受经直肠超声引导系统穿刺的男性,应建议重复(靶向)活检。

核心结论

  • 在多参数磁共振成像评分1–2分背景下,经直肠超声引导系统穿刺仅在1/20男性中发现Gleason 3+4疾病。
  • 对于任何临床显著前列腺癌定义,经直肠超声引导系统穿刺敏感性差,阴性预测值虽可变但较低。
  • 多参数磁共振成像评分3–5分且未行靶向穿刺而仅接受经直肠超声引导系统穿刺的男性,应建议重复(靶向)活检。

研究设计与样本

  • PROMIS(前列腺磁共振成像研究)中,因前列腺特异抗原升高和/或直肠指检异常拟行前列腺活检的初次活检男性接受多参数磁共振成像、经会阴模板定位穿刺和经直肠超声引导系统穿刺,活检均在其他检查结果盲法下进行和报告。
  • 41个月内共11个中心招募740例男性,其中576例完成全部3项检查。

主要发现

  • 多参数磁共振成像评分1–2分的150例男性中,8例(5.1%)经直肠超声引导系统穿刺发现任何Gleason 3+4或以上疾病。
  • 经直肠超声引导系统穿刺显示任何最大癌芯长度的Gleason 3+3的75例男性中,61例(81%)为Gleason 3+4,8例(11%)为Gleason 4+3,0例(0%)为Gleason 4+5或以上疾病。
  • 对于定义1(临床显著前列腺癌),经直肠超声引导系统穿刺敏感性在多参数磁共振成像Likert评分中保持稳定且低,为35%至52%。
  • 对于定义2(临床显著前列腺癌和任何癌症),敏感性随多参数磁共振成像评分升高而增加。
  • 阴性预测值因疾病患病率不同而变化,但对于所有癌症阈值,阴性预测值随多参数磁共振成像评分升高而下降。

关键数值与推荐

  • 临床显著前列腺癌主要定义为Gleason 4+3或以上,或任何分级最大癌芯长度≥6 mm。
  • 临床显著前列腺癌次要定义为Gleason 3+4或以上,或任何分级最大癌芯长度≥4 mm。
  • 经直肠超声引导系统穿刺对定义1临床显著前列腺癌的敏感性为35%至52%。

临床怎么用

  • 多参数磁共振成像评分3–5分且未行靶向穿刺而仅接受经直肠超声引导系统穿刺的男性,应建议重复(靶向)活检。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the performance of transrectal ultrasound guided systematic and transperineal template mapping biopsies with a 5 mm sampling frame stratified by the multiparametric magnetic resonance imaging Likert score in the PROMIS (Prostate MR Imaging Study). MATERIALS AND METHODS: Biopsy naïve men due to undergo prostate biopsy for elevated prostate specific antigen and/or abnormal digital rectal examination underwent multiparametric magnetic resonance imaging, and transperineal template mapping and transrectal ultrasound guided systematic biopsies, which were performed and reported while blinded to other test results. Clinically significant prostate cancer was primarily defined as Gleason 4 + 3 or greater, or a maximum cancer core length of 6 mm or more of any grade. It was secondarily defined as Gleason 3 + 4 or greater, or a maximum cancer core length of 4 mm or more of any grade. RESULTS: In 41 months 740 men were recruited at a total of 11 centers, of whom 576 underwent all 3 tests. Eight of the 150 men (5.1%) with a multiparametric magnetic resonance imaging score of 1-2 had any Gleason 3 + 4 or greater disease on transrectal ultrasound guided systematic biopsy. Of the 75 men in whom transrectal ultrasound guided systematic biopsy showed Gleason 3 + 3 of any maximum cancer core length 61 (81%) had Gleason 3 + 4, 8 (11%) had Gleason 4 + 3 and 0 (0%) had Gleason 4 + 5 or greater disease. For definition 1 (clinically significant prostate cancer) transrectal ultrasound guided systematic biopsy sensitivity remained stable and low across multiparametric magnetic resonance imaging Likert scores of 35% to 52%. For definition 2 (clinically significant prostate cancer and any cancer) sensitivity increased with higher multiparametric magnetic resonance imaging scores. The negative predictive value varied due to varying disease prevalence but for all cancer thresholds it declined with increasing multiparametric magnetic resonance imaging scores. CONCLUSIONS: In the setting of multiparametric magnetic resonance imaging Likert scores 1-2 transrectal ultrasound guided systematic biopsy revealed Gleason 3 + 4 disease in only 1 of 20 men. Further, for any clinically significant prostate cancer definition transrectal ultrasound guided systematic biopsy had poor sensitivity and variable but a low negative predictive value across multiparametric magnetic resonance imaging scores. Men who undergo transrectal ultrasound guided systematic biopsy without targeting in the setting of a multiparametric magnetic resonance imaging score of 3 to 5 should be advised to undergo repeat (targeted) biopsy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lovegrove CE, Miah S, El-Shater Bosaily A, et al. Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial. J Urol. 2019. PMID: 31335254. doi:10.1097/JU.0000000000000455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。